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Several hundred papers in the 
past seven years have established 
two new mechanisms of immunity, 
both of which are dependent 
upon proteins that deaminate 
cytosines to uracils within single-
stranded DNA. Activation-induced 
deaminase (AID) deaminates C -> 
U to implement the diversification 
of vertebrate antibody genes and 
mammalian APOBEC3 proteins, 
such as human APOBEC3F and 
APOBEC3G, deaminate C -> U to 
trigger the destruction of a wide 
variety of retroelements including 
HIV. Here, we will discuss how 
the purposeful deamination of 
DNA-based cytosines underpins 
integral parts of both the adaptive 
and the innate immune responses.
Antibody diversity
The generation of a large and 
diverse antibody repertoire 
is fundamental to our ability 
to respond to and neutralize 
invading pathogens. Antibody 
diversity is achieved by three 
distinct events that irreversibly 
alter the immunoglobulin gene 
DNA specifically in the B-cell 
lineage. The first process (which 
also generates functional 
T-cell receptor genes) is V(D)J 
recombination. Functional antigen 
receptor genes are assembled 
in a site-specific recombination 
reaction catalyzed by the RAG1 
and RAG2 enzymes, which 
juxtapose the germline-encoded 
variable (V), diversity (D) and 
joining (J) region DNA segments. 
Individuals that are unable to 
complete V(D)J recombination 
lack mature B and T lymphocytes, 
resulting in severe combined 
immunodeficiency.
B cells that have successfully 
completed V(D)J recombination 
migrate to lymphoid tissues 
Primer where they encounter specific antigens. These cells express 
surface immunoglobulin of the µ 
isotype (IgM) and secrete soluble 
antibodies with relatively low 
affinities. Co-stimulation of B 
cells by antigen and a specific 
T cell triggers further rounds 
of diversification via somatic 
hypermutation (SHM) and class 
switch recombination (CSR). 
SHM introduces non-templated 
point mutations into the antibody 
gene variable region. Such 
mutations occur at an extremely 
high frequency and can alter the 
affinity of the encoded antibodies 
without changing their effector 
function. Iterative rounds of SHM 
coupled to antigen-dependent 
selection are responsible for 
antibody affinity maturation. 
CSR is a switch-region-specific 
recombination reaction that 
replaces the µ constant region 
with one of the downstream 
constant regions, γ, α or ε, thereby 
changing the antibody isotype 
to IgG, IgA or IgE, respectively 
(e.g. recombination of Sµ and 
Sγ in Figure 1). These alternative 
antibody isotypes mediate a range 
of activities, including antigen 
neutralization and marking, 
gut homeostasis and allergic 
responses.
AID
Activation-induced deaminase 
(AID) was cloned by Honjo and 
coworkers in 1999 as a factor that 
was specifically upregulated in B 
lymphocytes induced to undergo 
CSR. Its similarity to the APOB 
mRNA editing catalytic protein 
1 (APOBEC1), which catalyzes 
specific mRNA C -> U deamination, 
suggested that AID might function 
in a similar manner. The interest in 
AID increased substantially when 
it was shown to be essential for 
CSR and, remarkably, also for SHM 
in mice and humans. Moreover, a 
seemingly unrelated mechanism 
of antibody gene diversification 
that occurs in birds and some 
other vertebrates, immunoglobulin 
gene conversion (IGC), was also 
shown to require AID. These 
data indicated that the yet-to-
be-defined mechanism would be 
as conserved though the entire 
vertebrate lineage as the antibody 
response itself.The surprising requirement 
for AID in all three antibody 
gene diversification processes, 
coupled with the fact that SHM 
is biased toward C/G base pairs 
in a variety of systems, helped 
lead Neuberger and colleagues 
to propose a unified model for 
antibody gene diversification, 
suggesting that all of these 
apparently distinct events are 
triggered by AID through the 
direct deamination of cytosines in 
DNA (Figure 1). In support of such 
a mechanism, AID expression in 
Escherichia coli caused a mutator 
phenotype and a C/G -> T/A 
transition mutation bias, which 
was exaggerated in the absence 
of the uracil excision enzyme, 
uracil DNA glycosylase (UDG). The 
generally accepted interpretation 
of these data was that AID could 
deaminate cytosines in DNA and 
the resulting non-repaired uracils 
(which base-pair like thymines) 
could template the incorporation 
of adenines and ultimately 
manifest as C/G -> T/A transition 
mutations. 
The importance of uracil
The potent DNA cytosine 
deaminase activity of AID has now 
been demonstrated in a variety of 
model genetic and biochemical 
systems. The notion that it is 
this activity that directly triggers 
antibody gene diversification is 
supported by the fact that the 
mutational preference of purified 
AID (i.e. its intrinsic activity) is 
similar to that observed in vivo 
in the antibody gene variable 
or switch regions: AID prefers 
to deaminate DNA cytosines 
preceded by an A/T base pair and 
a purine (i.e. 5’-WRC). 
A key prediction of the original 
DNA deamination model is that 
uracil is a central intermediate. 
The chicken B lymphocyte 
line DT40 can diversify 
immunoglobulin variable region 
DNA by IGC and also by SHM in 
some recombination-defective 
backgrounds. Normally DNA-
based uracils are removed and 
ultimately repaired by UDG. 
However, when this enzyme was 
specifically inhibited in DT40, 
a dramatic bias toward C/G -> 
T/A SHM patterns resulted. A 
similar shift was observed in the 
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the major UDG (UNG2). Such a 
mutational shift is consistent with 
the interpretation that all types of 
base substitutions can result from 
error-prone DNA synthesis over 
an abasic site (created by uracil 
excision), whereas transitions at 
C/G base pairs result simply from 
DNA synthesis over non-excised 
uracils. Moreover, subsequent 
studies showed that levels of CSR 
in mice and humans and of IGC 
in DT40 were strongly reduced 
by the UDG deficiency. Together, 
these data indicate that uracil 
excision is a crucial step in all 
three of these processes.
A second prominent DNA 
repair system is also capable 
of recognizing U/G mispairs. 
Mismatch repair (MMR) normally 
functions to remove post-
replicative lesions from DNA and, 
for more than a decade, has had 
a controversial association with 
SHM and CSR. However, recent 
experiments from the Neuberger 
group and others have clearly 
shown that the MSH2 protein is 
required, together with UDG, for 
aspects of SHM and for CSR. 
The CSR result is clear-cut, 
with both the UNG2- and the 
MSH2-deficient mice displaying 
lower levels of CSR and with the 
double mutant mice completely 
lacking non-IgM antibodies. The 
SHM result is more intriguing, 
with the UNG2-deficient mice 
showing a C/G -> T/A mutation 
bias and the MSH2-deficient 
(and the double mutant) mice 
showing dramatically fewer 
base substitution mutations 
at A/T bases (normally, base 
changes at A/T exceed those 
at C/G in humans and mice). 
This connection of mismatch 
repair to the A/T-directed SHM 
program has not been resolved 
mechanistically (although it is 
indeed also AID-dependent).
Directing AID
Now that considerable progress 
has been made towards 
understanding the mechanism 
of antibody gene diversification, 
a renewed attention is focusing 
on the question of how AID 
is targeted specifically to 
the immunoglobulin locus. A 
prominent feature of SHM and CRM1
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Figure 1. Antibody gene diversification triggered by AID. 
AID has a predominantly cytoplasmic localization and must therefore diffuse or actively 
transport into the nucleus by an as-yet-undefined mechanism. Once inside the nucleus, 
AID appears to be directed toward the immunoglobulin  variable and switch regions 
(e.g. Sμ), and concomitantly away from the immunoglobulin constant regions (e.g. Cμ) 
and the rest of the genome. This entire program is probably guided by AID-interacting 
proteins (AIPs). AIPs identified to date include DNA-PKcs, MDM2, PKA, RPA (32 kDa 
subunit) and RNA polymerase II. The PKA-dependent phosphorylation of AID is de-
picted. CRM1 escorts AID back to the cytoplasm. SHM, somatic hypermutation; IGC, 
immunoglobulin gene conversion; CSR, class switch recombination.IGC is that the events occur 
specifically within the expressed 
variable region, not even upstream 
of the promoter or downstream 
in the constant region (let alone 
in other expressed genes in B 
cells). Given the fact that AID 
is predominantly a cytoplasmic 
protein, how does it gain access 
to the antibody gene DNA whilst 
shuttling in and out of the nucleus 
(Figure 1)? Moreover, when doing 
so, how does AID avoid mutating 
the bulk of the genomic DNA?
Work from the Honjo and 
Nussenzweig groups has revealed 
that the carboxyl terminus of AID 
is required for nuclear export 
and, surprisingly, is essential for 
CSR (but not for SHM/IGC). In 
contrast to full-length AID, which 
predominantly localizes to the 
cytoplasm of B cells, AID lacking 
its last 10 amino acids appears 
to distribute throughout the cell. 
Moreover, incubating cells with the 
CRM1/Exportin1 nuclear export 
inhibitor leptomycin B caused a 
similar phenotype. Therefore, the 
export of AID from the nucleus is 
most likely mediated by the CRM1 
pathway. 
Further studies with this 
interesting AID carboxy-terminal 
deletion mutant revealed that this 
region is dispensable for SHM/IGC 
but not for CSR. A closer analysis 
of the switch region DNA from B 
cells expressing this AID variant 
showed an abundance of  AID-dependent base 
substitutions. One provocative 
interpretation of these data is that 
the carboxy-terminal domain of 
AID helps recruit a CSR-specific 
factor, which is required for the 
isotype switch mechanism, and 
that an SHM- (and/or IGC-)  
specific factor also exists. 
Indeed, some support for the 
latter possibility has come from 
studies of additional AID mutants 
suggesting that an amino-terminal 
region harbors SHM/IGC activity.
So, if CRM1 helps AID exit 
the nucleus, then one wonders 
how AID enters the nucleus and, 
more specifically, how it finds 
the expressed immunoglobulin 
genes. Recent studies from 
the Alt laboratory have shown 
that AID can interact with the 
32 kDa subunit of the single-
stranded DNA-binding protein 
complex, RPA. Biochemical 
data indicate that the binding 
of AID to RPA facilitates the 
deamination of transcribed 
WRC-rich immunoglobulin gene 
DNA. This is indeed plausible, 
but hard to rationalize as the 
sole AID-targeting mechanism, 
because many transcription 
and DNA replication, repair and 
recombination proteins have 
been shown to associate with 
RPA. Further work is necessary 
to explain, for instance, why AID 
is not attracted to RPA-bound 
DNA during replication, and to 
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Figure 2. Retroelement restriction triggered by APOBEC3 proteins. 
Endogenous and exogenous retroelement RNA is transcribed from elements integrated 
in the host genome and packaged into assembling particles. APOBEC3 (A3) proteins 
are incorporated into the particles (most likely through association with the viral Gag 
protein) and, upon reverse transcription (RT) of the viral RNA, they deaminate cytosines 
to uracils in the first strand cDNA. These events are followed by integration (INT) of 
the replicated retroelement DNA into the host cell’s genome. HIV Vif targets 
APOBEC3F/G for proteasomal degradation. APOBEC3-interacting proteins (AIPs) 
include the viral proteins Gag and Vif, and the cellular ubiquitin ligation complex 
CUL5/ELOB/ELOC/RBX.delineate the proteins that assist 
its nuclear entry.
The data from the Alt laboratory, 
in combination with a recent 
report from the Dalla-Favera 
group, also indicate that the 
nuclear-localized AID protein may 
be preferentially phosphorylated 
and that this specific 
phosphorylation is mediated by 
protein kinase A, which would 
neatly connect this event to cell 
signals that trigger antibody 
maturation. Nevertheless, other, 
as-yet-unidentified proteins are 
likely to be required for the proper 
targeting of AID to the antibody 
genes (Figure 1).
APOBEC3 DNA deaminases
AID is only one of at least ten 
putative or proven DNA cytosine 
deaminases encoded by the 
human genome. All of these 
proteins harbor a zinc-binding, 
cytosine deamination domain — 
HxE–x23–28–PCx2–4C — in which 
the histidine and the cysteines 
coordinate zinc and the glutamate 
participates in deamination. AID 
and APOBEC1, the founding 
member of this family, are 
encoded by chromosome 12, 
APOBEC2 by chromosome 
6 and APOBEC3A–3H by 
chromosome 22. Two members 
of the latter cluster, APOBEC3F 
and APOBEC3G, are cellular factors that can directly inhibit HIV 
infection. 
Retrovirus restriction 
APOBEC3G was identified as 
a dominant cellular factor that 
inhibited the replication of HIV 
variants lacking a small accessory 
protein called Vif. Several 
groups simultaneously showed 
that this ‘restrictive’ function of 
APOBEC3G was attributable to its 
entering newly synthesized virus 
particles, hitch-hiking with the 
particle to a new target cell and, 
during reverse transcription of the 
viral RNA genome, deaminating 
the nascent viral cDNA cytosines 
(Figure 2). The resulting uracils 
then template the incorporation of 
adenines, and a subsequent round 
of replication (or repair) accounts 
for the phenomenon that had been 
previously termed retroviral G -> 
A hypermutation. APOBEC3F has 
similarly potent anti-HIV activities 
and the combined mutation 
preferences of APOBEC3F and 
APOBEC3G account for the HIV 
hypermutation patterns observed 
in viral DNA sequences from AIDS 
patients.
If such a powerful defense 
mechanism operates in vivo, 
then how can HIV possibly 
replicate in humans and cause 
AIDS? Numerous groups 
independently showed that HIV Vif triggers the poly-ubiquitination 
and proteasome-dependent 
degradation of APOBEC3F 
and APOBEC3G. Biochemical 
studies from the Yu and Gabuzda 
groups have demonstrated 
the involvement of the CUL5-
ELOB/C-RBX ubiquitin ligase 
complex. Vif thereby essentially 
disarms the cell in which HIV is 
being produced. It is notable that 
other cellular (and viral) proteins 
are marked for degradation by 
ubiquitin, leading to speculation 
that other AID/APOBEC family 
members might be similarly 
regulated and perhaps even share 
a subset of interacting proteins.
An evolutionary conundrum
Obviously, inhibition of HIV, though 
important, is not the evolutionarily 
preserved function of the human 
APOBEC3 proteins. A number 
of facts strongly suggest that 
their true reason for existence 
may be to control endogenous 
retroelements. First, it is widely 
accepted that HIV entered the 
human population within the 
past hundred years, whereas 
the APOBEC3 proteins are 
approximately 100 million years 
old. Second, a comparison of 
primate and human APOBEC3 
protein sequences has indicated 
that they are almost all under 
a strong positive selective 
pressure(s) (i.e. the number 
of coding base changes far 
exceeds the number of silent 
base changes), suggesting 
the presence of a strong and 
probably ongoing genetic 
conflict. Third, recent work from 
several laboratories has shown 
quite convincingly that multiple 
APOBEC3 proteins, including 
APOBEC3F and APOBEC3G, are 
able to inhibit a broad spectrum of 
endogenous retroelements, such 
as the yeast retrotransposon Ty1 
and the murine IAP and MusD 
retroelements. Finally, the infective 
potential of many distantly related 
retroviruses can be blocked by 
a single APOBEC3 protein. For 
instance, APOBEC3G can restrict 
murine leukemia virus, equine 
infectious anemia virus, simian 
immunodeficiency virus, feline 
and simian foamy virus, human 
T lymphotrophic virus, human 
hepatitis B virus and, as previously 
Magazine
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observations combine to indicate 
that the restrictive potential of 
the APOBEC3 proteins is broadly 
applicable.
One possible mechanistic link 
is that many of the APOBEC3 
proteins seem to exploit the 
multifunctional and ubiquitous 
Gag protein in order to access 
the single-stranded DNA of 
replicating retroelements. Indeed, 
an association has been reported 
between APOBEC3G and the 
distantly related Ty1 and HIV Gag 
proteins. However, it is important 
to point out that Gag associates 
with RNA and that APOBEC3 
proteins can associate with 
RNA, so their mutual association 
may also be RNA mediated 
(a controversial issue in the 
literature). Structure–function 
studies are desperately needed to 
help shed additional light on this 
important area.
Directing APOBEC3
Like AID, APOBEC3F and 
APOBEC3G appear to have 
a predominantly cytoplasmic 
subcellular localization (Figure 2).  
This location seems like a sensible 
way to gain access to the cores 
of assembling retroelements, 
as well as keep the potentially 
hazardous mutator activity 
safely away from the genomic 
DNA of the cell. However, 
expression of APOBEC3G in 
yeast was recently shown to 
trigger genomic hypermutation. 
This implies that the DNA 
cytosine deaminase activity of 
APOBEC3G can penetrate both 
the eukaryotic nuclear membrane 
(omnipresent in S. cerevisiae) and 
chromatin. Thus, it is reasonable 
to postulate that, like AID, the 
human APOBEC3 proteins 
are tightly regulated. Recent 
studies from Greene’s laboratory 
support this contention, as they 
indicate that APOBEC3G can 
associate with a near mega-
dalton cellular complex. It is likely 
that APOBEC3F, which appears 
to be co-expressed and can 
interact with APOBEC3G, will also 
associate with the same complex. 
Additional work is necessary 
to define these and likely other 
cellular regulators of the human 
APOBEC3 proteins. Common origins
AID has a pivotal role in 
generating antibody diversity, 
and APOBEC3F/G clearly 
possesses the capacity to block 
retroelement replication. DNA 
cytosine deamination is key to 
both mechanisms. Although many 
of the other human APOBEC3 
proteins are still less well 
understood, it is likely that they 
may also have roles fortifying 
the innate immune defenses 
against pathogens lurking within 
our systems. Phylogenetic 
studies have suggested that 
the APOBEC3 proteins evolved 
from an AID-like ancestor. Taking 
this together with the fact that 
non-mammalian vertebrates 
lack APOBEC3 proteins, one 
might wonder whether the AID 
protein from such organisms 
might very well possess both 
antibody diversification and 
retroelement restriction activities? 
Thus, ancestral AID may 
have possessed retroelement 
restriction activities that were 
subsequently co-opted for 
antibody diversification and other 
biological processes. In other 
words, is AID the mother of all 
APOBECs?
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